Botulinum toxin A injection for post-stroke upper limb spasticity and rehabilitation practices from centers across Asian countries
Issued Date
2024-01-01
Resource Type
eISSN
16642295
Scopus ID
2-s2.0-85191078190
Journal Title
Frontiers in Neurology
Volume
15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Neurology Vol.15 (2024)
Suggested Citation
Rosales R.L., Chia N.V.C., Kumthornthip W., Goh K.J., Mak C.S., Kong K.H., Ng Y.S., Chou L.W., Flordelis M.J., Do T., Maisonobe P., Li L.S.W., Suputtitada A. Botulinum toxin A injection for post-stroke upper limb spasticity and rehabilitation practices from centers across Asian countries. Frontiers in Neurology Vol.15 (2024). doi:10.3389/fneur.2024.1335365 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98159
Title
Botulinum toxin A injection for post-stroke upper limb spasticity and rehabilitation practices from centers across Asian countries
Author's Affiliation
Siriraj Hospital
Metropolitan Medical Center, Manila
University of Santo Tomas, Manila
China Medical University Hospital
Kuala Lumpur Hospital
King Chulalongkorn Memorial Hospital
Singapore General Hospital
University of Malaya Medical Centre
Tung Wah Hospital
Ipsen
Faculty of Medicine, Chulalongkorn University
Tan Tock Seng Hospital
Perpetual Succor Hospital
Metropolitan Medical Center, Manila
University of Santo Tomas, Manila
China Medical University Hospital
Kuala Lumpur Hospital
King Chulalongkorn Memorial Hospital
Singapore General Hospital
University of Malaya Medical Centre
Tung Wah Hospital
Ipsen
Faculty of Medicine, Chulalongkorn University
Tan Tock Seng Hospital
Perpetual Succor Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: Describe real-life practice and outcomes in the management of post-stroke upper limb spasticity with botulinum toxin A (BoNT-A) in Asian settings. Methods: Subgroup analysis of a prospective, observational study (NCT01020500) of adult patients (≥18 years) with post-stroke upper limb spasticity presenting for routine spasticity management, including treatment with BoNT-A. The primary outcome was goal attainment as assessed using goal-attainment scaling (GAS). Patients baseline clinical characteristics and BoNT-A injection parameters are also described. Results: Overall, 51 patients from Asia were enrolled. Rates of comorbid cognitive and emotional problems were relatively low. Patients tended to have more severe distal limb spasticity and to prioritize active over passive function goals. Most (94.1%) patients in the subgroup were treated with abobotulinumtoxinA. For these patients, the median total dose was 500 units, and the most frequently injected muscles were the biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%). Overall, 74.5% achieved their primary goal and the mean GAS T score after one treatment cycle was 56.0 ± 13.0, with a change from baseline of 20.9 ± 14.3 (p < 0.001). The majority (96.1%) of Asian patients were rated as having improved. Conclusion: In the Asian treatment setting, BoNT-A demonstrated a clinically significant effect on goal attainment for the real-life management of upper limb spasticity following stroke.